Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMDA-mitomycin C vs BCG in high-grade non-muscle invasive bladder cancer
2024-520006-19-00Phase 4Authorised
- Sponsor
- Presurgy
- Start
- Jan 2025
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of mitomycin c and bcg vaccine in bladder cancer (2 arms), sponsored by Presurgy. Primary endpoint: 5-year tumor recurrence rate. Planned start Jan 2025; status: authorised.
02
Drugs
mitomycin cbcg vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2024-520006-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520006-19-00.